Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06136650
What this trial is testing

Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,314
Early research (Phase 1)Study completedNCT00405210
What this trial is testing

Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Who this might be right for
Primary DiseaseProstate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 38
Testing effectiveness (Phase 2)Study completedNCT01560923
What this trial is testing

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota 47
Large-scale testing (Phase 3)Study completedNCT01234311
What this trial is testing

Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Active Biotech AB 1,245
Large-scale testing (Phase 3)Study completedNCT00638690
What this trial is testing

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Who this might be right for
Prostatic Neoplasms
Cougar Biotechnology, Inc. 1,195
Testing effectiveness (Phase 2)Ended earlyNCT05633160
What this trial is testing

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Who this might be right for
Prostatic NeoplasmsCastration-Resistant
Clarity Pharmaceuticals Ltd 4
Testing effectiveness (Phase 2)Study completedNCT02036060
What this trial is testing

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

Who this might be right for
Metastatic Prostate Cancer
Spanish Oncology Genito-Urinary Group 119
Testing effectiveness (Phase 2)Ended earlyNCT04102124
What this trial is testing

SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 20
Early research (Phase 1)Study completedNCT01607905
What this trial is testing

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Who this might be right for
Solid Tumor
Karyopharm Therapeutics Inc 192
Early research (Phase 1)UnknownNCT03780075
What this trial is testing

Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital 50
Not applicableUnknownNCT04188275
What this trial is testing

CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION

Who this might be right for
D011471D064129D035683+2 more
Azienda Ospedaliero-Universitaria Careggi 46
Early research (Phase 1)Ended earlyNCT02349139
What this trial is testing

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Cancer of the ProstateNeoplasms, ProstateProstate Cancer+3 more
Asana BioSciences 27
Testing effectiveness (Phase 2)UnknownNCT04963595
What this trial is testing

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Zhiyong Yu 100
Large-scale testing (Phase 3)Looking for participantsNCT07354022
What this trial is testing

Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 912
Testing effectiveness (Phase 2)UnknownNCT04824937
What this trial is testing

Telaglenastat + Talazoparib In Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Massachusetts General Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT06764485
What this trial is testing

Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Celgene 960
Testing effectiveness (Phase 2)UnknownNCT06251492
What this trial is testing

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Fudan University 30
Testing effectiveness (Phase 2)Ended earlyNCT04812535
What this trial is testing

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Who this might be right for
SCC - Squamous Cell Carcinoma of Skin
InflaRx GmbH 30
Early research (Phase 1)Study completedNCT02162836
What this trial is testing

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Janssen Pharmaceutical K.K. 6
Not applicableStudy completedNCT00491140
What this trial is testing

Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab

Who this might be right for
Colorectal Neoplasms
Istituto Clinico Humanitas 85
Next Page